N/A
Completed N=26
Racial Differences in Phosphorus Metabolism
Control
Source: ClinicalTrials.gov NCT00856726 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcomePrimary: Urinary Phosphorus Excretion — 11 percentage of fractional excretion
Summary
The investigators aim to study potential racial differences in renal phosphorus handling by provocatively testing urinary phosphorus excretion using parathyroid hormone infusions in healthy white volunteers compared to healthy black volunteers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urinary Phosphorus Excretion |
11 | — |
| SECONDARY Fibroblast Growth Factor 23 |
10 | — |
| SECONDARY Serum Phosphorus |
0.4 | — |
| SECONDARY Serum Calcium |
0.4 | — |
| SECONDARY Parathyroid Hormone |
9 | — |
| SECONDARY Fractional Excretion of Calcium |
0.25 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Body mass index (BMI) within 20% ideal for their age and gender
Exclusion Criteria
- Abnormal urinalysis
- Pregnancy or breast-feeding
- Medical conditions impacting phosphorus metabolism-primary hyperparathyroidism; diabetes mellitus; gastrointestinal malabsorption disorders; hyper- or hypothyroidism
- Medications known to affect phosphorus metabolism- current use of phosphorus supplements, phosphorus binders, calcitriol or calcitriol analogues, regular antacid or laxative use, calcitonin, etidronate, anticonvulsants
- Hyper- or hypophosphatemia (≥ 4.6 mg/dl or ≤ 2.5 mg/dl respectively), hyper- or hypocalcemia (≥ 10.6 or ≤ 8.5 mg/dl respectively), or severe anemia (Hgb < 8 g/dl for women and < 9 g/dl for men)
Data sourced from ClinicalTrials.gov (NCT00856726). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.